AS/Spondyloarthritis
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Dr. John Cush RheumNow
4 years 1 month ago
Video: The PsA SpA Paradox of Choice
Dr. Rachel Tate ( @uptoTate) reviews Dr. Laura Coates' presentation Personalized Treatment Strategies in Psoriatic Arthritis, given at the virtual #EULAR2021 meeting.
https://t.co/Yg12SHR1MF https://t.co/UiCYDU5XGc
Dr. John Cush RheumNow
4 years 1 month ago
Video: Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi (@MeralElRamahiMD ) #EULAR2021
https://t.co/ocyR4ka8zO https://t.co/DxHjM0stKo
Dr. John Cush RheumNow
4 years 1 month ago
#EULAR2021 - Day 3 Report
https://t.co/X7zxsKW8eL https://t.co/OKu5Mgodlo
Here are a few notable presentations from this past Friday, Day 3 of the EULAR 2021 virtual meeting.
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has provided much-needed reassuring answers.
Dr. John Cush RheumNow
4 years 1 month ago
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot.
https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 1 month ago
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 1 month ago
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 1 month ago
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
Eric Dein ejdein1
4 years 1 month ago
#EULAR2021 POS0236
Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort
⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA
Can use to counsel AxSpA patients that we have effective Rx for return to work
@RheumNow
Eric Dein ejdein1
4 years 1 month ago
#EULAR2021 POS0237: Gut dysbiosis linked to worse disease status in axSpA.
⭐️Dysbiosis in 33% of AxSpA vs 17% of controls wo rheumatic disease
⭐️Gut dysbiosis associated with worsening disease activity
@RheumNow https://t.co/rRl4Zbs7xc
David Liew drdavidliew
4 years 1 month ago
6. Rheum disease activity was stable with COVID vaccination.
(RA, PsA, axSpA, SLE - total n = 597)
7/
LB0003 #EULAR2021 @RheumNow https://t.co/xxkrunjPa0
Dr. John Cush RheumNow
4 years 1 month ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.
Poster Hall